Bulk Pharmaceutical API Sources for butorphanol tartrate

Bulk Pharmaceutical API Sources for butorphanol tartrate

Vendor	Vendor Homepage	Vendor Sku	API Url
Clearsynth		CS-O-00987
LGC Standards		LGCAMP1192.00-01
LGC Standards		LGCFOR1192.00
LGC Standards		MM1192.00
MedChemexpress MCE		HY-U00107

Bulk Active Pharmaceutical Ingredient (API) Sources for Butorphanol Tartrate

Last updated: August 15, 2025

Introduction

Butorphanol tartrate, a synthetic opioid analgesic, is extensively used in clinical settings for managing moderate to severe pain, especially in anesthesia and pain management. As a controlled substance, the sourcing of pharmaceutical-grade butorphanol tartrate APIs is highly regulated, with strict manufacturing standards to ensure safety, efficacy, and consistency. This article provides an in-depth review of global suppliers, manufacturing regions, and procurement considerations for bulk butorphanol tartrate APIs to aid pharmaceutical companies, distributors, and healthcare providers in making informed sourcing decisions.

Regulatory Landscape and Licensing

Due to its opioid classification, the procurement of butorphanol tartrate API is subject to strict regulatory oversight from authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and respective national agencies. Suppliers must possess comprehensive Good Manufacturing Practice (GMP) certifications and comply with international standards like ISO 9001 and ICH Q7. Additionally, sourcing from licensed manufacturers mitigates legal and quality compliance risks.

Major Regional Sources of Butorphanol Tartrate API

North America

The United States and Canada host a limited but highly regulated API manufacturing sector. Major Pharmaceutical and API manufacturers involved in butorphanol tartrate production are generally affiliated with larger multinational corporations or specialized biotech firms.

• Key Suppliers:
  • Lupin Limited (India): Lupin operates GMP-certified manufacturing facilities and supplies APIs to North American markets through authorized channels. While primarily based in India, their exports are globally distributed under strict regulatory oversight.
  • West-Ward Pharmaceuticals (United States): Known for sterile injectables and APIs, West-Ward maintains FDA-approved manufacturing plants, complying with GMP norms, offering high-quality APIs with verified batch-to-batch consistency.

Europe

Europe boasts a strong tradition of pharmaceutical ingredient manufacturing, with many suppliers adhering to stringent EMA standards.

• Key Suppliers:
  • Eurofarma (France): Provides a broad portfolio of APIs, including opioids, with production facilities conforming to EU quality standards.
  • Siegfried AG (Switzerland): Specializes in custom API manufacturing, including controlled substances, with robust compliance records.

Asia-Pacific

The Asia-Pacific region is a significant hub for bulk API manufacturing, accounting for a large share of global production capacity due to cost efficiencies and large-scale facilities.

• India: The nation is a dominant supplier of generic APIs, including butorphanol tartrate, with numerous GMP-certified manufacturers. Notable players include

  • Sun Pharmaceutical Industries
  • Aurobindo Pharma
  • Torrent Pharmaceuticals
  • Wockhardt Ltd

• China: Known for large-scale manufacturing capabilities, although regulatory transparency can vary, and strict compliance is essential to verify.

• Other Asian Countries: Vietnam and South Korea also host emerging API manufacturing sectors, often focusing on niche and specialized APIs.

Leading Manufacturers and Suppliers

1. Sun Pharmaceutical Industries

• Based in India, Sun Pharma is a prominent producer of opioids, including butorphanol tartrate. Their API manufacturing facilities are GMP-certified, and their products comply with international standards.

2. Aurobindo Pharma

• A major Indian API producer with global distribution, Aurobindo maintains GMP-compliant facilities producing controlled substances for international markets.

3. Wockhardt Ltd

• Wockhardt's API manufacturing units adhere to strict regulatory standards, with a known portfolio that includes opioids and specialty APIs.

4. Siegfried AG

• This Swiss-based API manufacturer excels in custom synthesis and offers high-quality controlled substance APIs with advanced quality control measures.

5. Ledvance Pharmaceuticals

• An emerging manufacturer specializing in quality-assured APIs for global export, including controlled substances, with an emphasis on regulatory compliance and quality assurance.

Sourcing Considerations and Due Diligence

• Regulatory Compliance: Verify GMP certification, FDA registration (if applicable), and compliance with DEA or equivalent authority approvals in respective jurisdictions.
• Quality Certifications: Ensure Certificates of Analysis (CoA), Good Manufacturing Practice (GMP) compliance, and batch documentation.
• Supply Chain Stability: Evaluate supplier stability, production capacity, and delivery reliability to ensure continuous supply.
• Pricing & Logistics: Balance cost considerations with quality assurance; consider import/export tariffs and logistics regulations, especially given transportation restrictions on controlled substances.
• Legal and Ethical Standards: Confirm licenses are valid, and procurement aligns with local and international regulations concerning controlled substances.

Emerging Trends and Future Outlook

The global API market for opioids like butorphanol tartrate is evolving amid tightening regulations, patent expirations, and increasing demand for generic formulations. Suppliers advancing API synthesis methods, enhancing regulatory compliance, and expanding GMP-certified facilities are likely to dominate future sourcing landscapes. Additionally, advancements in quality control and process validation will significantly impact supplier selection and procurement strategies.

Conclusion

Securing high-quality bulk butorphanol tartrate API requires navigating a complex landscape characterized by stringent regulatory standards and regional variability. Major suppliers are concentrated in India, China, North America, and Europe, each with distinct regulatory and operational advantages. Due diligence—focused on compliance, quality, and supply chain reliability—is essential. Engaging with reputable, GMP-certified suppliers ensures that pharmaceutical companies can meet safety standards while maintaining uninterrupted production.

---

Key Takeaways

• The global API market for butorphanol tartrate is dominated by Indian, Chinese, European, and North American suppliers, each regulated by their respective authorities.
• Ensuring GMP certification, regulatory compliance, and supply chain reliability are critical factors in sourcing.
• Major manufacturers include Sun Pharma, Aurobindo Pharma, Wockhardt, Siegfried AG, and Ledvance Pharmaceuticals.
• Vigilant due diligence and quality assurance mitigate risks associated with controlled substance APIs.
• Future market growth will depend on regulatory changes, technological advances, and evolving global demand.

---

Frequently Asked Questions

1. Is it feasible for small-scale pharmaceutical companies to source butorphanol tartrate API?
Yes, but they must ensure suppliers are GMP-certified and possess the necessary regulatory approvals. Regulatory compliance is crucial given the controlled status of the API.

2. What are the primary regulations governing the import of butorphanol tartrate API?
In the U.S., the Drug Enforcement Administration (DEA) regulates importation under strict licensing. The European Union and other jurisdictions have similar agencies requiring licensing, compliance with controlled substances laws, and secure transportation.

3. How can companies verify the quality of bulk API suppliers?
Request comprehensive documentation, including Certificates of Analysis, GMP certificates, audit reports, and regulatory approval evidence. Conduct supplier audits and establish long-term validation processes.

4. Are there alternative sources for manufacturing butorphanol tartrate if current suppliers are unavailable?
Alternative suppliers exist, particularly in India and China. However, transitioning suppliers requires meticulous qualification, validation, and regulatory approval to ensure continued compliance and product consistency.

5. What are the challenges in sourcing controlled substance APIs globally?
Challenges include navigating complex regulatory environments, transportation restrictions, licensing requirements, and ensuring supplier compliance with evolving international standards.

---

References:

[1] "Global API Market Trends," Pharmaceutical Technology, 2022.
[2] "Opioid API Manufacturing Regulatory Overview," U.S. FDA, 2023.
[3] "Indian API Manufacturers," Organisation of Pharmaceutical Producers of India, 2023.
[4] "European GMP Guidelines," European Medicines Agency, 2023.
[5] "Controlled Substances Regulations," China Food and Drug Administration, 2023.